Pharming Receive EMA’s Approval to Establish New Facility for Manufacturing Ruconest (conestat alfa)

 Pharming Receive EMA’s Approval to Establish New Facility for Manufacturing Ruconest (conestat alfa)

Pharming Receive EMA’s Approval to Establish New Facility for Manufacturing Ruconest (conestat alfa)

Shots:

  • The approval will increase the production capacity of Ruconest and allows Pharming to release the therapy manufactured at the facility during the approval process for commercialization in the EU
  • The news facility is expected to reduce the risk of short-term pressure on the supply of Ruconest in the EU market targeting the needs of patients with hereditary angioedema
  • Ruconest is a recombinant human C1 esterase inhibitor, approved to treat HAE attacks in the US, EU, Israel and South Korea with the expected approval for the establishment of its new facility in the US in H1’20

Click here to­ read full press release/ article | Ref: Pharming  | Image: Solebury Trout Access

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post